Articles tagged with Breast Cancer
Medical University of South Carolina researchers found that advanced glycation end products (AGEs) can hamper response to tamoxifen therapy for ER-positive breast cancer patients. Lifestyle interventions, such as exercise and dietary counseling, may help reduce AGE levels and improve treatment outcomes.
A study using monkeys with the breast cancer drug letrozole found significant behavioral changes and impaired brain function, including hot flashes, increased anxiety, and spatial memory issues. The research highlights the importance of studying the effects of estrogen-reducing treatments on the nervous system.
A new approach to treating tumors has been discovered by regulating vascularization through a gene that is overexpressed in the tumor vasculature. By targeting the insulin receptor, scientists hope to deliver treatments more accurately and effectively.
Researchers have developed a novel portable optical imaging system that enables real-time visualization of tumor microenvironment in human breast tissue shortly after surgery. The system provides molecular features of breast cancer tissue, allowing for more accurate diagnoses and tracking of tumor progression.
A new analysis in BJS reveals that women requiring breast-conserving surgery re-operation pay £4,511 more in hospital costs than those with clear margins. This finding emphasizes the importance of reducing re-operation rates to achieve significant cost savings.
Two new studies published in the British Journal of Cancer reveal alarming breast cancer risks for women with false-positive screening results. Women who experience a first false-positive result have a two-fold risk of developing screen-detected or interval breast cancer later in life, while those with a second false-positive result fa...
Researchers analyzed data from over 1,000 breast cancer patients and identified seven clusters of patients based on their immune evasion mechanisms. This study provides a better understanding of how breast cancer hides from the immune system, allowing oncologists to develop more personalized treatment options.
Women who have given birth experience a lower risk of breast cancer, but this protective effect may not begin until as many as 30 years after the last pregnancy. A new study found that breast cancer risk increases in the years following childbirth, with the highest risk about five years later.
Researchers identify DPYSL3 as a molecule whose expression is altered in Claudin-Low triple-negative breast cancer, a highly metastatic and aggressive subtype. The study suggests that targeting the connection between DPYSL3 and vimentin could lead to new treatments for this disease.
A new study found that combining mammography with a novel imaging technique called three-compartment breast (3CB) imaging can significantly reduce unnecessary breast biopsies. The technique uses AI algorithms to analyze tissue composition, improving the ability to predict cancer and reducing recalls by up to 36%.
A new study found that young women with hormone receptor-positive luminal A breast cancer have a lower five-year disease-free survival rate compared to older patients. The study's authors hope their findings can inform better treatment options for this age group.
Researchers found that breastfeeding and family history of breast cancer had no impact on the increased risk. Risk peaked five years after childbirth, with a 80% higher risk compared to childfree women, but decreased by age 50. The study could inform screening decisions and prevention strategies.
Researchers at Tel Aviv University discovered that breast cancer tumors recruit stromal cells from bone marrow, boosting tumor cell proliferation and blood vessel formation. This finding highlights the potential for targeting these cells with novel therapies to treat the disease.
A UCLA-led research team has developed a spray gel that can awaken the immune system to stop cancer from recurring and spreading. The substance was successful half of the time in lab animals, with 50% survival rate after treatment.
Breastfeeding did not mitigate increased cancer risk, and older women are more susceptible to enhanced risks. The study analyzed data from 15 prospective studies and found that the heightened risk continued for about 24 years after childbirth.
The Canadian Task Force on Preventive Health Care updates its guideline to emphasize shared decision-making between women and their doctors. The new recommendations favor regular mammography screening for women aged 50-74, but only if they prefer it, due to uncertain benefits and harms.
The new TAILORx trial data reveals racial disparities in breast cancer outcomes, with 83.1% white women alive and cancer-free after nine years, compared to 78.9% black women. The study suggests biological factors contribute to the differences, regardless of treatment type or duration.
A study of 561 young women with breast cancer found that those who underwent mastectomy scored lower in quality of life measures, including satisfaction with appearance, psychosocial well-being, and sexual well-being. Breast-conserving surgery was associated with better outcomes, regardless of whether one or both breasts were removed.
A study found that younger breast cancer patients who underwent mastectomy reported lower breast satisfaction and poorer psychosocial and sexual well-being compared to those who had breast-conserving surgery. The researchers also found similar physical function across all groups.
Breast cancer survivors who participated in a lifestyle intervention program lost weight and had higher disease-free survival rates compared to those who received general recommendations. The study found that completion of the program was associated with a 35% higher rate of disease-free survival.
A multigene test used in breast cancer treatment helps doctors decide on chemotherapy, improving prognosis and reducing unnecessary treatments. The study found that patients with high-risk tumors had a five-fold increased risk of metastases and lower disease-free survival rates without chemotherapy.
Women who underwent supervised exercise during adjuvant breast cancer treatment experienced better cardiovascular function than those who didn't. The study found that exercise improved VO2 max and reduced decline in cardiovascular strength, particularly in patients receiving chemotherapy.
Treatment with oxybutynin significantly decreased the frequency and intensity of hot flashes in breast cancer survivors, improving their quality of life. The study found that patients on both oxybutynin doses experienced significant reductions in hot flash symptoms and improvements in overall quality of life.
Michael Hall's discovery of the TOR protein as a central controller of cell growth and metabolism has contributed to our understanding of cancer development. Rapamycin and its derivatives are now used in targeted cancer treatment, extending life expectancy for some patients with advanced cancer.
Recent studies at SABCS 2018 highlight radiation therapy's efficacy in treating breast cancer, with trials refining treatments to provide more options for patients. Accelerated partial breast irradiation has been shown to be non-inferior to traditional whole breast irradiation.
A new study published in a medical journal found that black women with early-stage breast cancer have worse outcomes than white women, even after receiving the same treatment. The study analyzed data from over 10,000 patients and found that black women had a lower survival rate and higher recurrence of invasive breast cancer.
Patients with early-stage breast cancer who had a positive sentinel lymph node biopsy showed comparable 10-year recurrence and survival rates following axillary radiotherapy or axillary lymph node dissection. The study also found that axillary radiotherapy was associated with significantly less lymphedema, a common side effect of surgery.
A phase III trial found that using circulating tumor cell count to guide treatment choice can lead to a significant gain in overall survival. Patients with estrogen receptor-positive, HER2-negative metastatic breast cancer who received chemotherapy based on high CTC counts had better progression-free and overall survival rates.
The study found that accelerated partial breast irradiation (PBI) was not statistically superior to whole breast irradiation (WBI) in preventing ipsilateral breast tumor recurrence. However, PBI showed promise as a less burdensome treatment option for some women, with smaller differences in relapse-free interval and grade 3 toxicity.
Researchers at University of Pennsylvania have developed new diagnostic tools to measure PARP-1 and glutamine levels in breast cancers. These biomarkers can help identify patients most likely to benefit from targeted therapies, offering a non-invasive way to guide treatment.
Advanced breast cancer patients with detectable PIK3CA mutations in their blood show improved progression-free survival when treated with alpelisib added to fulvestrant. Liquid biopsy analysis reveals a 45% risk reduction compared to tissue biopsy.
A large clinical trial found that black women with hormone-receptor positive breast cancer had a higher risk of recurrence and death compared to white women, even when treated equally. The study suggests biological differences may contribute to the disparity in outcomes.
A phase III trial found T-DM1 significantly reduced invasive disease-free survival risk in patients with HER2-positive early-stage breast cancer and residual invasive disease after neoadjuvant chemotherapy and trastuzumab. The treatment also showed promise in reducing recurrence risk across various subgroups of patients.
Pathological complete response after neoadjuvant chemotherapy was associated with lower recurrence risk and higher overall survival in breast cancer patients. The association between pCR and outcomes was similar among those who received additional adjuvant chemotherapy versus those who did not.
A recent study presented at EuroEcho-Imaging 2018 suggests that breast cancer patients who take the beta-blocker carvedilol together with trastuzumab have better-preserved left ventricular function compared to those who take trastuzumab alone. This may indicate that carvedilol can help prevent heart damage caused by trastuzumab treatment.
A retrospective study found that patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy had a significantly higher risk of disease recurrence and death. The study suggests that initiating chemotherapy within 30 days after surgery is crucial for improving disease-free and overall survival rates.
A recent study found that adding adjuvant capecitabine to standard treatment did not significantly improve disease-free or overall survival for patients with early-stage triple-negative breast cancer. However, a subset of patients with nonbasal-like disease showed a significant benefit from capecitabine.
Researchers at UC San Diego School of Medicine developed a method to turn B cells into factories that assemble and secrete vesicles containing tumor-suppressing microRNAs. In mice, breast tumors treated with this approach were significantly smaller than untreated tumors, and the treatment was long-lasting.
Researchers at SWOG share findings from three studies on breast cancer subtypes, treatment response, and recurrence. The studies used existing trial data to identify subsets of patients and tumors with distinct characteristics, which can inform treatment decisions.
Researchers at Lund University identified three types of connective tissue cells that affect breast cancer development and metastasis. Patients with vascular fibroblasts or matrix fibroblasts in their tumours have a worse prognosis.
A recent study found that around 72% of women at higher risk of breast cancer are worried about the long-term effects of tamoxifen, while 57% believe it will give them unpleasant side-effects. Despite its proven ability to prevent breast cancer, fewer than 15% of women with discussed preventive therapy are taking tamoxifen.
Scientists have developed a new system to rapidly and accurately detect tumor margins during breast cancer surgery, using a 'click-to-sense' acrolein probe that conjugates with live breast cancer cells. The method has been shown to be highly sensitive and selective, with a 97% accuracy rate.
A new smartphone app designed for breast cancer survivors has been shown to help patients achieve significant weight loss and improvements in physical activity. The app, created at Houston Methodist, allows users to interact with their healthcare team and receive real-time feedback and guidance from a clinical dietitian.
Researchers have reported promising preliminary results for cryoablation as a treatment for low-risk breast cancers, with a 99.4% success rate and no serious adverse events. The procedure is being studied as an alternative to surgical lumpectomy.
Researchers at the University of California San Diego have developed a simple 3D bioprinting technique using natural materials to create lifelike organ tissue models. The method allows for the creation of vascularized human gut and blood vessel networks capable of keeping cancer tumor tissues alive outside the body.
A large-scale study found that annual mammography screening starting at age 30 may benefit women with specific risk factors. Women with dense breasts, a personal history of breast cancer, or a family history of breast cancer had increased breast cancer risk and benefited from earlier screening.
Researchers have discovered that dasatinib sensitizes triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Additionally, a systematic review and meta-analysis found an increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy.
A new study found that breast cancer treatment correlates with accelerated biological aging and declines in cognitive function. Women who underwent breast cancer treatment several years earlier showed lower executive function scores, attention, and motor speed due to higher DNA damage and lower telomerase activity.
Researchers found that breast tumors can recruit bone marrow-derived fibroblasts to boost growth and metastasis. These cells lack key signaling proteins and produce clusterin, promoting blood vessel formation and tumor progression.
A new study confirms that women aged 75 and older should continue receiving mammography screenings due to the significant risk of breast cancer in this age group. The research found a considerable incidence of breast cancer among women over 75, with most cases being invasive and treatable.
A new report from the American Cancer Society proposes key areas to advance cancer screening's contribution to cancer control. Research is needed to improve existing screening modalities, quality and performance of current tests, and develop new strategies for cancers amendable to screening.
Research reveals that women who undergo reconstructive surgeries using a large back muscle after radiation therapy experience significant losses in shoulder stability and function. Conversely, other methods such as pectoral muscle rebuild and abdominal tissue transfer produce equally good results for future shoulder function.
Scientists at UNC Lineberger Comprehensive Cancer Center develop a computer algorithm to analyze breast cancer images and identify tumor characteristics. The AI system achieves high accuracy in distinguishing between low-intermediate and high-grade tumors, as well as estrogen receptor status and molecular subtypes.
Researchers found that flunarizine can slow down the growth of triple-negative breast cancer in an animal model, and it promotes N-Ras degradation. This approach is quicker and less expensive than traditional drug development strategies.
Researchers are testing Precision Breast IORT, which uses advanced imaging to tailor radiation treatment and potentially improve outcomes for patients with early-stage breast cancer. The study aims to evaluate the technique's effectiveness in reducing breast cancer recurrence rates and immune-dampening effects.
Purdue University researchers have developed a technology that uses nanoparticles to target cancerous cells and tumors, providing more effective and safer chemotherapy treatment. The method has been tested on breast cancer and melanoma models and shows promise for treating various types of cancerous tumors.
Researchers found two genomic tests, MammaPrint and BluePrint, can predict patient response to new treatments. These tests identified subgroups of patients with high-risk tumours more likely to respond to specific therapies.
Scientists at EPFL have found that half of luminal epithelial breast cells express estrogen receptor at low levels, affecting cell function and cancer development. The estrogen receptor plays a biphasic role in breast cell growth and inhibition during pregnancy.
Women who participate in breast screening have a significantly lower risk of dying from breast cancer within 10 and 20 years after diagnosis. The study found that screening detects cancers at an earlier stage, allowing for more effective treatment and a reduced mortality rate.
Researchers have developed a new strategy against HER2-driven lung cancers using tarloxotinib, a potent HER2/EGFR inhibitor that is more active in low-oxygen conditions than existing therapies. This innovative approach has shown significant promise in treating patients with HER2 lung cancer.